Save MISCPRODUCT Cheatsheet downloaded from and read

Guarantee that you have MiscVendor MISCPRODUCT PDF Download of genuine inquiries for the Miscellaneous Product (Payment as directed by sales) Exam prep before you step through the genuine examination. We give the most refreshed and legitimate MISCPRODUCT Dumps that contain MISCPRODUCT actual test questions. We have gathered and made a data set of MISCPRODUCT questions and answers from real

Exam Code: MISCPRODUCT Practice exam 2022 by team
Miscellaneous Product (Payment as directed by sales)
MiscVendor study help
Killexams : MiscVendor study help - BingNews Search results Killexams : MiscVendor study help - BingNews Killexams : People Keep Misreading & Misunderstanding This Important New Study on Depression & Medication

As if the world required any more misunderstanding around mental health, a new study showing depression isn’t caused by low levels of serotonin is, indeed, contributing to it. “News” to which every Escitalopram lover responded: “Yay, I can’t wait to try and convince more people who already don’t vibe with mental health — including social media who will invariably misinterpret this study — that, yes, this antidepressant is very much necessary.”

The research in question is a 2022 study published in Molecular Psychiatry that considers 17 studies and their findings regarding the link between brain chemistry and depression. Results showed their review of research on serotonin — the “happy hormone” — revealed “no convincing evidence that depression is associated with, or caused by, lower serotonin concentrations or activity.”

More from SheKnows

“Most studies found no evidence of reduced serotonin activity in people with depression compared to people without, and methods to reduce serotonin availability using tryptophan depletion do not consistently lower mood in volunteers,” the study’s authors wrote.

They continued: “The idea that depression is the result of a chemical imbalance also influences decisions about whether to take or continue antidepressant medication and may discourage people from discontinuing treatment, potentially leading to lifelong dependence on these drugs.”

Click here to read the full article.

Sound the warning bells because statements like these can be easily interpreted to mean antidepressants aren’t effective. But instead, what researchers are noting is that targeting serotonin as the main event may be misinformed.

“Many of us know that taking paracetamol can be helpful for headaches and I don’t think anyone believes that headaches are caused by not enough paracetamol in the brain,” Dr. Michael Bloomfield told BBC News.

Furthermore, one of the study’s authors, Joanna Moncrieff, told the news outlet that more research is needed to show how serotonin-targeted antidepressants help — or don’t help — patients beyond the first few months of using them.

(Pause to emphasize more research, not more ignorance. Say it twice and then continue reading.)

Far-right, mental health debunkers like transphobic Daily Wire host Matt Walsh, applauded the “findings” as proof that pointed at anti-depressants inefficacy.

“This anti-depressant study is huge,” he wrote on Twitter. “Big Pharma has made billions prescribing wonder drugs to treat depression but there was never any solid scientific evidence that the drugs would work. Now we know that the whole thing was built on a myth. Big Pharma’s greatest scam of all time.”

Not that anyone is surprised by this gross misinterpretation of the findings, but it doesn’t make it any less harmful.

“This research offers analyses to summarize some well-known facts about depression,” Mitch Prinstein, chief science officer for the American Psychological Association, said in a statement to Changing America, according to The Hill. Prinstein also emphasized that “the review’s findings emphasize why it’s critical to advance research to develop and test a variety of personalized psychological treatments,” the publication reported.

“First, depression is a very heterogeneous disorder; there are many different expressions of depression that come from a wide array of causal factors and present themselves differently from person to person,” he continued. “Second, there is no single treatment approach that works for everyone with depression.”

But with 17.3 million American adults struggling with depression on the line, one approach is clear: Continuing research to find the best answers. Period. Hands down. No questions asked.

Before you go, check out some of the best (and most affordable) mental health apps we swear by:


Launch Gallery: These Movies & TV Shows deliver An Honest Look at the Reality of Living With Clinical Depression

Best of SheKnows

Sign up for SheKnows' Newsletter.
For the latest news, follow us on Facebook, Twitter, and Instagram.

Fri, 05 Aug 2022 10:02:00 -0500 en-US text/html
Killexams : Nurse Navigators Can Help Alleviate Medical Distrust, Excellerate Clinical Trial Enrollment

African American patients with cancer are more likely to enroll in a clinical trial if their primary oncologist is one of the trial investigators, according to a presentation from the 6th Annual School of Nursing Oncology meeting. 1 Moreover, findings showed that African American patients with lung cancer are just as, if not more, knowledgeable about clinical trial enrollment as White patients with lung cancer, and highlighted that 1 key barrier to enrollment between the 2 groups may be an issue of trust.

“The way [respondents] expressed themselves was telling in terms of the trust for the physician,” Faith Mutale, CRNP, of the Abramson Cancer Center at the University of Pennsylvania, who presented the findings during the meeting, said in an interview with Oncology Nursing News®. “Some of the participants would say, ‘I don’t trust the medical system, but I trust my physician because they’ve shown interest in my individual well-being.’ ”

Understanding the role that trust plays in clinical trial enrollment is crucial for efforts to diversify research, Mutale added, particularly among the African American community, where there has been a history of abuse and misinformation.

Less than 5% of patients in the general population with cancer enroll in clinical trials.2 Among African American patients with cancer, enrollment rates are even fewer, even though African Americans comprise about 13% of the United States population.3 For other minorities, enrollment numbers are even lower.

The reason for lower enrollment rates is multifaceted, Mutale said. However, obtaining a better understanding of what motivates these patients to enroll was part of the impetus behind a clinical project that Mutale helped launch at her institution.

The study looked at 2 different sites within the Matrix Cancer Centers, comprising different ethnic populations. One center has a mixed racial population and the other primarily treats African American patients. The cohort size was 65 patients, and the primary end point was to explore clinical trial knowledge and factors that influence attitudes and willingness to enroll onto a clinical trial among African American patients with lung cancer using a survey.

“We were going into this project with several assumptions, one of which was [that] participants from the primary site were more likely to have clinical trial knowledge and interest to enroll, as opposed to the affiliate site,” Mutale said. “But that wasn’t [the case].”

How can oncology nurses address this lack of trust?

According to Mutale, nurses will be at the forefront of bridging this barrier to care. Specifically, nurse navigators may play a role in helping keep patients both informed, and well-advocated, as they navigate the process of clinical trial enrollment.

“Nurse navigators have the ability to inform or educate patients about what’s available,” Mutale explained. “Patients may not be very comfortable discussing these things upfront, particularly after the first visit. However, they may then go the navigator and talk about what [clinical trials] are and what this may mean for them.”

Alongside nurse navigators, social workers have the potential to make patients feel both at ease, and well supported throughout their cancer journey, Mutale added. “Some of our patients just felt very comfortable talking to someone who looked like them,” she said, emphasizing that it’s not just the information that matters, but feeling as though your provider understands you and is invested in your well-being that is critical as well.

“In my experience, having a navigator and a social worker has always been very helpful. Their presence can [have] a calming effect in a nonthreatening way,” she said.

Overall, a paradigm shift is necessary in oncology, according to Mutale. At an institutional level, there is a need is a need to develop nurse-driven programs to combat disparities in clinical trial enrollment. There also needs to be a push for specific training for the role of the “clinical trial educator,” as Mutale calls them. “I coined this particularly nurses who are members of minority groups. Patients must feel and know that the providers interest goes beyond the trial but for each individual patient outcomes as well.”

Based on these findings from the phase 1 part of the study, investigators are now launching a phase 2 study.


  1. Mutale FA. Sandy B. Inclusion of minorities in cancer clinical trials: where are we now? Presented at: 6th Annual School of Nursing Oncology®; July 29-30, 2022; San Diego, CA.
  2. Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. Am Soc Clin Oncol Educ Book. 2016;35:185-198. doi:10.1200/EDBK_156686
  3. Siegal RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7-33. doi:10.3322/caac.21654
Mon, 01 Aug 2022 06:00:00 -0500 Lindsay Fischer en text/html
MISCPRODUCT exam dump and training guide direct download
Training Exams List